advertisement
AIM: To evaluate the protective effect of Erigeron Breviscapus (Vant.) Hand-Mazz (EBHM) on the visual field of the glaucoma with controlled intraocular pressure (IOP). METHODS: Twenty-four cases (40 eyes) of primary glaucoma with visual field defect and the IOP less than 18 mmHg were enrolled. The tablets were taken orally according to the randomized and double-masked principle, and the tablets were divided into EBHM and placebo respectively. Each patient took the tablets for three times a day and 2 tables each time, with 2months as a course, continuing for 3 courses. All patients must receive the visual field examination and clinical observation every 2 months. At the end of the study, the drug provider fed back the message. RESULTS: 1. No significant difference was found between before and after treatment in all courses of the two groups in systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse, IOP, C/D, visual acuity (P > 0.05). There were no obvious side effects in all the patients. 2. There were significant differences in mean defect (MD) and mean sensitivity (MS) of the treated group between before treatment and after 6months treatment. 3. For the middle and late stage glaucoma, there were significant differences in MD and MS of the treated group between before treatment and after 2, 4 and 6months treatment, respectively. CONCLUSION: Decreasing IOP may have partial protective effect for the visual function in some glaucoma patients. EBHM may have partial protective effect in visual function of primary glaucoma with controlled IOP. The longer the EBHM administration course is, the more obviously the improvement of visual field defect is. For the middle and late stage primary glaucoma, the improvement of visual field with EBHM is more significant. EBHM has no effect on BP, pulse, IOP, visual acuity or C/D ratio. LA: Chinese
Dr. M.-H. Xiang, Department of Ophthalmology, Putuo Hospital, Shanghai Chinese Traditional Medicine University, Shanghai 200062, China
11.15 Other drugs in relation to glaucoma (Part of: 11 Medical treatment)
11.8 Neuroprotection (Part of: 11 Medical treatment)